FDA's Inspection Mission Grew. Its Experienced Investigator Pipeline Did Not.

The Food and Drug Administration oversees products representing about 21 cents of every dollar U.S. consumers spend. Its regulatory reach covers more than $3.9 trillion in food, drugs, medical devices, tobacco, cosmetics and other products made in the United States and abroad.

That mission expanded between fiscal 2008 and 2024. Funding grew too, increasingly through industry user fees. But inspection capacity did not rise cleanly with either responsibility or money. Government reviews found persistent problems recruiting, retaining and training the investigators who turn statutory authority into visits to factories, laboratories, clinical-research sites and food facilities.

The clearest example is FDA's drug-investigation workforce. Vacancies among investigators handling domestic and foreign manufacturers rose from 25 in November 2021 to 51 in June 2024, while an inexperienced workforce limited the number of inspections FDA could complete. New investigators can need two to three years before they conduct foreign inspections independently.

This is not proof that every missed inspection produced an unsafe product. FDA uses risk-based targeting and other oversight tools, and inspection counts alone do not measure public health. It is evidence that the agency's practical oversight capacity depends on experienced people it has struggled to keep.

Inspection authority grew faster than a simple mission statement

Congress added major responsibilities over the period reviewed by the Government Accountability Office. Tobacco regulation expanded after 2009. The Food Safety Modernization Act directed FDA to increase inspection frequency for certain food facilities. A 2022 law broadened cosmetics oversight, including recall authority in specified circumstances.

FDA's overall resources grew from fiscal 2008 through 2024, with user fees accounting for much of the increase. The funding mix shifted from mostly discretionary budget authority toward a roughly even split between budget authority and user fees. Those fees can be tied to particular product programs and commitments; they are not a single flexible pool that automatically solves every staffing gap.

GAO's review did not say FDA lacked all capacity. It documented a mismatch across responsibilities, experienced personnel, information technology and inspection execution. The agency had completed a strategic workforce plan in 2024, but officials told GAO in early 2025 that it was no longer current. As of December 2025, most related GAO recommendations discussed in the review were not fully implemented.

Drug investigators were hired and lost at the same rate

A separate GAO investigation of drug safety shows why gross hiring is a weak success measure. From the start of fiscal 2022 through June 2024, FDA's general pool of about 230 authorized drug investigators hired 105 people and lost 105.

Annual turnover in that pool was 22% in fiscal 2022 and 22% in 2023. It was 13% through June 2024. The 105 losses included employees who moved to other FDA positions, left the agency or retired. Internal movement may preserve talent for FDA while still removing inspection capacity from the pool.

FDA identified travel, pay, training, workload and work-life balance as root causes. Drug investigators can travel as much as 75% of the time. The agency had initiatives addressing pay and training, but GAO found no complete action plans for travel, workload and work-life balance because reducing those burdens could also reduce near-term inspection output.

That tradeoff is real. Sending experienced investigators on more trips can raise current inspection volume while accelerating burnout. Pulling them back to train new staff can improve future capacity while lowering output today. A sustainable plan has to measure both.

Experience is a separate capacity measure

FDA told GAO that 63% of its drug investigators had been hired within the previous five years as of May 2024. In June 2024, 36% of the general pool lacked the experience needed to conduct independent foreign inspections.

Foreign inspection roles are built from the experienced general pool. Investigators normally need two to three years before working abroad independently, and specialized foreign assignments require prior foreign-inspection experience. A vacancy can therefore be filled on a personnel roster long before the employee replaces the capability that left.

This experience ladder affects domestic work too. Senior investigators train newer colleagues and may complete fewer inspections while doing so. The same on-board headcount can support different output depending on tenure, qualification and assignment.

Clinical-research inspections show a related pattern. GAO found that FDA's bioresearch monitoring investigator workforce had declined since 2018, with persistent attrition, compensation concerns and travel burden. Those inspectors verify the integrity and protection systems behind data used in medical-product decisions. The product category differs, but the human-capital mechanism is similar.

The whole FDA workforce contracted sharply after 2024

FederalHiringData's calculation from OPM monthly employment files shows the covered FDA workforce at 21,026 in December 2024 and 16,240 in June 2026, a decline of 4,786 employees, or 22.8%.

That is an agency-wide civilian count, not an inspector count. It includes scientists, reviewers, analysts, managers, technologists, attorneys and support staff across FDA. Organizational changes and coding can affect the series. It should not be used to claim that FDA lost 4,786 inspectors.

The direction is still important. The decline occurred after GAO had already documented an inspection workforce with retention and experience problems. To determine the operational effect, FDA would need to publish current occupation-level staffing, qualifications, vacancies and inspection output under its post-2025 structure.

The public data currently answer the broad workforce question more confidently than the narrow capacity question. Covered agency employment fell. The exact number of experienced investigators available by product area and inspection type in June 2026 is not established by the OPM total.

Recruiting history shows a specialized labor market

The FederalHiringData historical USAJOBS archive contains 10,816 distinct announcements matched to FDA from March 2017 through Aug. 13, 2026. Consumer safety was the leading specialized series with 1,407 announcements. Biological science, health science, chemistry, microbiology, pharmacology, biomedical engineering and medical officers also appeared prominently.

Annual announcements peaked at 1,834 in 2018, reached 1,606 in 2020 and fell to 901 in 2024. The archive contains 93 announcements in 2025 and 82 in partial 2026 coverage through Aug. 13. Those totals are not hires, and a reorganization can change which organization name appears on an announcement. They do show that FDA's recruiting mission spans occupations with significant technical training.

Consumer-safety officers and investigators do not become interchangeable with chemists, physicians or IT staff because they share an agency. FDA's inspection capacity depends on the right skill in the right program, supported by laboratories, data systems and regulatory specialists.

Repeat recruiting can signal a difficult labor market, expansion or routine use of standing registers. Without applicant, offer, acceptance and retention data, it cannot distinguish among them. That missing conversion funnel is central to evaluating whether the agency's hiring remedies worked.

Inspection counts require a denominator and a risk context

Pandemic restrictions interrupted many in-person inspections beginning in 2020. FDA had largely resumed domestic and foreign drug-manufacturing inspections by March 2022, but foreign inspections had not returned to pre-pandemic levels in GAO's 2024 review.

Inspection volume alone is not a quality score. FDA can target higher-risk facilities, use records requests, rely on certain foreign regulatory partners and adjust frequency under law. A smaller number of better-targeted inspections could be more useful than a larger number of low-value visits.

At the same time, some reported inspection totals need closer definition. GAO found that attempted domestic food inspections represented nearly one-third of the inspections FDA counted toward a statutory mandate from 2018 through 2023. An attempted inspection could occur when an investigator arrived but the facility was not operating. GAO recommended reducing those unsuccessful attempts so limited staff time produced more completed oversight.

The most informative public measure would pair completed inspections with the relevant establishment universe, risk tier, investigator capacity and follow-up results. Domestic and foreign facilities should remain separate. So should food, drugs, devices and clinical research, whose legal frameworks and inspection processes differ.

What recovery would look like

Inspection recovery should be visible in more than a rising headcount. FDA would need a lower vacancy rate among qualified investigators, lower unwanted attrition, a larger share able to work independently, and completed inspections that meet risk-based program goals.

The agency also needs to retain the mentors who create future capacity. If experienced staff spend much of their time training new hires, current output may temporarily lag even while the workforce becomes healthier. That would be a legitimate investment if FDA measures and discloses the transition.

GAO's open recommendation asks FDA to address travel, workload and work-life balance while preserving inspection needs. That is harder than adding a hiring campaign. It requires the agency to decide how much travel is sustainable, where pay or incentives matter, how training will be staffed and which work can be redesigned.

Related research

Put this finding in context

All articles

Data investigations/August 20, 2026

634 Applications, Eight Completed Rotations: Why the Federal Cyber Exchange Stalled

Employees showed interest in the federal cyber rotation program. Home-agency approval, unreimbursed staffing costs and senior qualification demands narrowed the path.

Data investigations/August 21, 2026

DOE Has an $8 Billion Cleanup Mission. Its Federal Oversight Workforce Fell to 856.

DOE's nuclear-cleanup office lost one-third of its federal staff in two years while engineering, contracting and safety-related vacancies widened.

For job seekers, historical FDA announcements show a deep market for scientific and regulatory skills, but past postings are not open vacancies. Readers can browse current federal jobs, compare health and science occupations and explore agency hiring. For oversight, the key public question is whether FDA's current workforce can convert funding and authority into experienced inspection capacity.

Food, drugs and clinical research cannot share one inspection rate

FDA's inspection programs operate under different laws, risk models and facility universes. Drug-manufacturing inspections assess production controls and data in a global supply chain. Food inspections cover an enormous domestic and foreign establishment base and can involve federal, state and contract partners. Bioresearch monitoring focuses on the integrity of clinical research and protections for participants. Device and veterinary programs have additional requirements.

That diversity makes an agency-wide inspections-per-employee ratio nearly meaningless. The relevant denominator is the trained workforce available to the program, while the numerator must distinguish completed, attempted, domestic, foreign, routine, surveillance and for-cause inspections.

Food oversight shows the partnership problem. State and contract inspectors may conduct work on FDA's behalf, so a federal headcount decline does not translate one-for-one into fewer visits. The agency still needs federal employees to set standards, oversee partners, analyze findings and take regulatory action. A useful dashboard would show partner work separately, not erase it from the total or count it as federal labor.

Foreign drug inspections present the opposite constraint: travel, language, diplomatic access and the need for experienced investigators can make each assignment harder to staff. GAO's finding that more than a third of the general pool lacked independent foreign-inspection experience in June 2024 identifies a qualification bottleneck that a raw vacancy rate misses.

Clinical research adds another specialist pipeline. Inspectors must understand trial conduct, records and data integrity. GAO found persistent attrition and a less experienced bioresearch monitoring workforce. Combining that problem with food or drug manufacturing would hide the program-specific training demand.

Capacity can fall even when funding rises

User-fee growth may support additional personnel and systems within authorized programs, but money does not instantly produce qualified investigators. Hiring takes time, and the experience ladder takes years. Travel conditions, workload and private-sector opportunities can undo recruiting gains through attrition.

Funding also comes with constraints. A fee collected for one product program may not be available for another mission. Congressional directives can add inspection frequency or new product responsibilities while implementation depends on hiring, training, data systems and partner agreements.

That is why GAO's 2008-24 review paired funding with responsibilities and workforce challenges. The relevant test is whether resources, authorities and skilled capacity move together. In the current public record, the first two are documented more completely than the third.

A recovery claim should therefore identify the specific inspection program, qualified staff available, facility universe, completed work and risk-based target. Without those elements, a higher agency budget or headcount remains an input rather than evidence that oversight capacity recovered.

Methodology and limitations

Mission, funding and cross-program findings come from GAO-26-107779, published Feb. 3, 2026. Drug-investigator vacancy, turnover and experience findings come from GAO-25-106775. Clinical-research context comes from GAO's 2024 review of the bioresearch monitoring workforce.

FederalHiringData calculated monthly covered FDA employment from OPM Federal Workforce Data from January 2015 through June 2026. The series is agency-wide and is not used as an inspector count. We counted distinct historical USAJOBS control numbers matched to FDA from March 1, 2017 through Aug. 13, 2026. Announcements are recruiting activity, not vacancies filled, inspections performed or employees retained. The 2026 total is partial.

Product values, consumer-spending shares, vacancy figures and inspection findings retain the scope and dates used by their source agencies. We do not infer that fewer inspections automatically caused weaker safety outcomes. Readers can review current jobs, federal workforce statistics, agency pages and more data investigations.